The beverage behemoth’s latest quarterly results delivered a complex narrative for investors. While profitability metrics showed strength, revenue performance and a significant strategic impairment charge have introduced fresh concerns about the company’s near-term trajectory.
Coca-Cola’s financial report for the fourth quarter of 2025 presented a dichotomy. On a positive note, the company’s comparable earnings per share (EPS) increased by 6% to $0.58, slightly exceeding Wall Street’s expectations. This growth was attributed to effective cost control measures and a 5% rise in organic revenue, largely fueled by strategic pricing actions.
However, the top-line figures told a different story. Net revenue climbed by a modest 2% to reach $11.8 billion, falling notably short of the consensus estimate of approximately $12.05 billion. This divergence between profit performance and sales growth has become a focal point for market analysis.
A major development overshadowing the quarterly figures was Coca-Cola’s announcement of a substantial non-cash impairment charge. The company wrote down the value of its BodyArmor sports drink brand by approximately $960 million. This move follows Coca-Cola’s full acquisition of the Gatorade competitor in 2021 for $5.6 billion. The significant valuation adjustment signals that the brand has failed to meet the aggressive growth targets initially set by management. The charge had a material, negative impact on the company’s reported operating margins for the period.
Looking ahead to the 2026 fiscal year, Coca-Cola’s management has adopted a conservative stance, citing uncertain global economic conditions. The company is forecasting organic revenue growth in a range of 4% to 5%. For comparable EPS, it anticipates an increase of 7% to 8% from the prior year’s base of $3.00.
Should investors sell immediately? Or is it worth buying Coca-Cola?
This guidance coincides with a planned change at the helm. CEO James Quincey is scheduled to pass the leadership role to current Chief Operating Officer Henrique Braun at the end of March 2026. Quincey will remain with the company as Executive Chairman. The incoming CEO will immediately face the dual challenge of steering the corporation through a complex international marketplace and addressing the underperformance within the BodyArmor segment.
The market’s response to the mixed report was decidedly negative. In trading sessions following the earnings release, Coca-Cola shares declined between 2% and 4%, pulling back from recent highs. For shareholders, the combination of softer-than-expected revenue and the large impairment charge currently outweighs the solid underlying profit growth. All eyes are now on the incoming leadership team and their ability to generate renewed momentum starting in April of next year.
Fresh Coca-Cola information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
